Home 2022
Yearly Archives: 2022
News
New Advanced Therapy Treatment Centre established in London to improve clinical trial infrastructure
The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy...
FDA approves Lilly’s EBGLYSS for adults and children 12 years and older with moderate-to-severe...
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults...
HAYA Therapeutics collaborates with Lilly to discover novel regulatory genome targets for obesity and...
HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, has announced a multi-year agreement with Eli Lilly and Company...
